drugset / Trial / NCT01033032
Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
Doxorubicin has been an integral part of the treatment of women with breast cancer for many years. Since amrubicin may have more activity than doxorubicin, as well as less cardiotoxicity, evaluation of amrubicin in the treatment of advanced breast cancer should be a priority. In this Phase II study, the investigators propose an evaluation of single-agent amrubicin as second- or third-line treatment for women with metastatic breast cancer.
Timeline
- Start
- 2009-12
- Primary completion
- 2013-07
- Completion
- 2014-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amrubicin | Small molecule | 90 mg/m2 | Intravenous |
| Subject | Amrubicin | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Amrubicin | Small molecule | 110 mg/m2 | Intravenous |
| Subject | Amrubicin | Small molecule | 120 mg/m2 | Intravenous |